High-energy microwave thermotherapy in the treatment of benign prostatic hyperplasia

被引:2
作者
Cavarretta, L [1 ]
Scremin, E [1 ]
Cucciarré, G [1 ]
Todeschini, M [1 ]
Novella, G [1 ]
Tasca, A [1 ]
机构
[1] San Bortolo Hosp, Dept Urol, I-36100 Vicenza, Italy
关键词
benign prostatic hyperplasia; transurethral microwave thermotherapy;
D O I
10.1159/000071086
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Transurethral microwave thermotherapy is an anesthesia-free, outpatient method of treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). Our results with the use of this technique in 25 patients are reported. Materials and Methods: Twenty-five patients with BPH, 8 of whom with complete urinary retention, were treated with high-energy transurethral microwave thermotherapy (HE-TUMT) (Prostatron system). Preoperative investigations included digital rectal examination, urinary free flow rate, PSA, urinalysis, urine culture, transrectal ultrasonography, urodynamic evaluation, International Prostatic Symptom Score (IPSS) and quality of life (QoL). Main selection criteria included: large prostate, high surgical risk, reluctance to undergo surgery. All patients were obstructed according to the Abrams-Griffith's nomogram. For the statistical analysis a repeated-measures, one-way ANOVA was performed on previously non-catheterized patients. Results: Six of the 8 patients with catheter before treatment were able to urinate spontaneously with no significant post-voiding residual urine. In the 17 remaining patients, IPSS decreased from a mean of 18.5 at baseline to 7.30 and QoL from a mean of 3.9 to 1.2. Mean maximum flow rates during uroflowmetry increased from 8.5 to 16.9 ml/s. P-det Q(max) decreased from a mean of 83.0 cm H2O at baseline to 50.7 cm H2O and Q(max) increased from a mean of 6.8 ml/s at baseline to 15.1 ml/s during the pressure-flow study. After TUMT, 13 patients were unobstructed and 4 equivocal according to the Abrams-Griffith's nomogram. Conclusion: Our study performed in a selected population of patients with BPH documents the efficiency and safety of HE-TUMT. This technique appears to be a valid therapeutic option, particularly in patients with high surgical risk. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:10 / 15
页数:6
相关论文
共 50 条
[41]   Pharmacological treatment of benign prostatic hyperplasia [J].
Oelke, M. ;
Martinelli, E. .
UROLOGE, 2016, 55 (01) :81-94
[42]   Individualization of treatment in benign prostatic hyperplasia [J].
Altwein, JE .
EUROPEAN UROLOGY, 1996, 29 :2-6
[43]   LASER TREATMENT OF BENIGN PROSTATIC HYPERPLASIA [J].
MUSCHTER, R ;
HOFSTETTER, A .
UROLOGE-AUSGABE A, 1994, 33 (04) :281-287
[44]   Pharmacological treatment of benign prostatic hyperplasia [J].
Oelke, M. ;
Kuczyk, M. A. ;
Herrmann, T. R. W. .
UROLOGE, 2009, 48 (11) :1365-1375
[45]   Phytotherapy in the treatment of benign prostatic hyperplasia [J].
Bracher, F .
UROLOGE-AUSGABE A, 1997, 36 (01) :10-17
[46]   Dutasteride for the treatment of benign prostatic hyperplasia [J].
Wu, Christopher ;
Kapoor, Anil .
EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (10) :1399-1408
[47]   Tadalafil for the treatment of benign prostatic hyperplasia [J].
Monica, Fabiola Zakia ;
De Nucci, Gilberto .
EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (08) :929-937
[48]   Options for the Treatment of Benign Prostatic Hyperplasia [J].
Plante, Mark ;
Wachterman, Jared ;
Perrapato, Scott .
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2012, 22 (04) :281-287
[49]   Association of the Benign Prostatic Hyperplasia and erectile dysfunction, the current treatment modalities in Benign Prostatic Hyperplasia [J].
Sen, Volkan ;
Demir, Omer ;
Esen, Ahmet Adil .
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2011, 10 (04) :62-64
[50]   A new prostatic stent for the treatment of benign prostatic hyperplasia in high-risk patients [J].
Traxer, O ;
Anidjar, M ;
Gaudez, F ;
Saporta, F ;
Daudon, M ;
Cortesse, A ;
Desgrandchamps, F ;
Cussenot, O ;
Teillac, P ;
Le Duc, A .
EUROPEAN UROLOGY, 2000, 38 (03) :272-278